Aug 13, 2020
KAHR Medical to Present at Oppenheimer's Private Life Sciences Company Call Series
Aug 12, 2020
KAHR Medical Announces FDA Clearance of IND Application for DSP107, anti-CD47 Candidate for the Treatment of Solid Tumors
Jun 02, 2020
World Market for Next Generation Immune Checkpoint Inhibitors and Stimulators - Forecast and Opportunity Analysis
Jun 01, 2020
Innovent Announces the Preliminary Results of the Anti-PD-1/PD-L1 Bispecific Antibody IBI318 in a Phase 1 Clinical Study
May 25, 2020
Innovent Announces First Patient Dosed in A Phase 1 Clinical Trial of Anti-TIGIT Monoclonal Antibody in China
Apr 23, 2020
SITC Announces Three Recipients of the 2020 Richard V. Smalley, MD, Memorial Award and Lectureship
Mar 30, 2020
Alphamab Oncology, Simcere and 3D Medicines Announce Partnership to Develop and Commercialize Subcutaneous Injectable anti-PD-L1 Antibody for Oncology Indications in Mainland China
Mar 17, 2020
The PD-1 and PD-L1 Inhibitors Industry, 2020-2030 - Provides Detailed Analysis of 19+ Products along with 15+ Companies Involved
Feb 25, 2020
KAHR Medical Raises $18 Million in Private Funding Round
Feb 20, 2020
Agenus Announces Positive Interim Data from Balstilimab and Zalifrelimab Clinical Trials in Second-Line Cervical Cancer
Jan 22, 2020
Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22, a Subcutaneously Administered PD-L1 Antibody
Jan 13, 2020
Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma
Jan 07, 2020
Beta Lifescience Announces the Online Availability of Quality Immune Checkpoint Proteins for Scientific Discoveries
Jan 07, 2020
Innovent and Sirnaomics Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining Sintilimab and RNAi in the US
Jan 07, 2020
Sirnaomics and Innovent Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining STP705 and Sintilimab in the US
Dec 18, 2019
IncellDx Signs Liquid Biopsy Distribution Agreement with Singapore-based Biolidics, Inc.
Dec 12, 2019
CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia
Dec 05, 2019
Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-LAG-3 Monoclonal Antibody in China
Nov 21, 2019
iOmx Therapeutics' iOTarg(TM) Genetic Screening Platform Featured in Podium Presentation at PEGS Europe 2019
Nov 12, 2019
Biomica Reports Positive Preliminary Results in Animal Studies in Its Immuno-oncology Program